5-alpha reductase inhibitor
Finasteride
Finasteride is an oral type II 5-alpha reductase inhibitor. US labels give a mean terminal half-life of about 5 to 6 hours in men 18 to 60 and tablets of 1 mg for hair loss and 5 mg for prostate enlargement.
Finasteride after one dose: 50% at ~6 h, 25% at 12 h, 12.5% at 18 h.
Drawn from the half-life in the app's model, ~6 h. The model's figures
- Compound
- Finasteride
- Symbol
- FIN
- Family
- Post-cycle and ancillaries
- Parts
- 14
- References
- 11
- Checked
- Last reviewed . Sources are listed below.
Overview
Sources in this part
Finasteride is an inhibitor of type II 5-alpha reductase, an intracellular enzyme that converts testosterone into dihydrotestosterone (DHT).1 In the United States Organon sells it as Propecia, a 1 mg tablet indicated for male pattern hair loss (androgenetic alopecia) in men only, and as Proscar, a 5 mg tablet indicated for symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate.1,2 The Propecia label states that it is not indicated for use in women, and in a 12-month study of 137 postmenopausal women with androgenetic alopecia (67 on Propecia, 70 on placebo) effectiveness could not be demonstrated.1
The app lists a half-life of about 6 hours, oral bioavailability of 65%, a time to peak of about 2 hours and a typical dose of 1 to 2 mg a day. The Propecia label gives a mean terminal half-life of 4.5 hours after an intravenous dose and approximately 5 to 6 hours in men 18 to 60 years of age, the Proscar label gives 6 hours, and the Propecia label gives a time to peak of 1 to 2 hours and a dose of 1 mg a day.1,2 None of the labels or trials cited here reports a daily dose of 2 mg.
How it works
Sources in this part
The enzyme
The label states that the type II 5-alpha reductase isozyme is primarily found in prostate, seminal vesicles, epididymides and hair follicles as well as liver, and is responsible for two-thirds of circulating DHT.1 In in vitro binding studies on native scalp and prostate tissue, finasteride showed a 100-fold selectivity for the human type II over the type I enzyme.1 The label gives the turnover of the enzyme complex as slow, with a half-life of approximately 30 days for the type II complex.1
In people
The label states that the balding scalp of men with male pattern hair loss contains miniaturized hair follicles and increased amounts of DHT compared with hairy scalp, and that finasteride decreases scalp and serum DHT concentrations in these men.1 It also states that the relative contributions of these reductions to the treatment effect have not been defined.1 Serum DHT reached 65% suppression within 24 hours of a 1 mg tablet, and daily 5 mg for up to 4 years reduced serum DHT by approximately 70%.1,2
Pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~6 h
- Bioavailability
- 65%
- Typical dose
- 1–2 mg/day
- Route
- Oral
- Time to peak
- ~2 h
Sources in this part
| Parameter | Value | Note |
|---|---|---|
| Half-life | ~6 hours (the app's figure) | Propecia label: mean terminal half-life 4.5 hours (range 3.3 to 13.4; n=12) after intravenous infusion, and approximately 5 to 6 hours in men 18 to 60 and 8 hours in men over 70. Proscar label: mean 6 hours (range 3 to 16).1,2 |
| Bioavailability (oral) | ~65% (the app's figure) | Propecia label: mean 65% (range 26 to 170%) for 1 mg tablets in 15 healthy young men, not affected by food. Proscar label: mean 63% (range 34 to 108%) for 5 mg tablets.1,2 |
| Time to peak | ~2 hours (the app's figure) | Propecia label: at steady state on 1 mg a day (n=12) the maximum plasma concentration averaged 9.2 ng/mL and was reached 1 to 2 hours after the dose, with a mean time to peak of 1.3 hours (SD 0.5).1 |
| Typical dose | 1 to 2 mg a day (the app's figure) | Propecia label: one 1 mg tablet once daily. Proscar label: one 5 mg tablet once a day.1,2 |
| Route | Oral | Both labels are for oral tablets.1,2 |
Finasteride is extensively metabolized in the liver, primarily via the cytochrome P450 3A4 enzyme subfamily, and the two metabolites identified have no more than 20% of its 5-alpha reductase inhibitory activity.1 After an oral dose of 14C-finasteride in 6 men, a mean of 39% of the dose was excreted in urine as metabolites and 57% in feces.1 Approximately 90% of circulating finasteride is bound to plasma proteins, and the label states that finasteride has been found to cross the blood-brain barrier.1
The chart uses the app's half-life of 6 hours and time to peak of 2 hours with the once daily schedule on the Propecia label.1
Level over 4 days
Level, as a share of the peak after one 1 mg dose
As studied: every day1.
An illustration from a pharmacokinetic model using a half-life of 6 hours. It is not a measured level or a suggested dose.
Human studies
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Kaufman and colleagues, 19983 | Two randomised, placebo-controlled 1-year trials with blinded second-year extensions; first author at Merck Research Laboratories; no sponsor stated in the source text | 1553 men aged 18 to 41 with male pattern hair loss; 1215 continued into year 2 | Finasteride 1 mg a day or placebo, 1 and 2 years | Vertex hair count (baseline 876 hairs, 1-inch circle) was 107 and 138 hairs higher than placebo at 1 and 2 years (P<.001); placebo gave progressive hair loss |
| Propecia label, clinical studies, 20231 | Three double-blind, randomised, placebo-controlled 12-month studies, extensions to 5 years; label issued by Organon | 1879 men aged 18 to 41 with mild to moderate hair loss (88% Caucasian); 1553 with vertex loss, 326 with anterior mid-scalp loss | Finasteride 1 mg a day, 12 months; extensions up to 5 years | Vertex hair count difference from placebo: 107 hairs at 12 months (n=679 vs 672), 138 at 2 years (433 vs 47), 277 at 5 years (219 vs 15), all p<0.001; by blinded photograph rating at 5 years, 48% increase, 42% no change and 10% loss on finasteride against 6%, 19% and 75% on placebo |
| Olsen and colleagues, 20064 | Randomised, placebo-controlled; no sponsor stated in the source text | 416 men aged 21 to 45 with male pattern hair loss | Dutasteride 0.05, 0.1, 0.5 or 2.5 mg, finasteride 5 mg, or placebo daily, 24 weeks | Dutasteride raised target area hair count against placebo in a dose-dependent way, and 2.5 mg was superior to finasteride 5 mg at 12 and 24 weeks; the authors state: "The study was limited to 24 weeks." |
| Thompson and colleagues, 20035 | Randomised, placebo-controlled Prostate Cancer Prevention Trial; grants listed from the National Cancer Institute | 18,882 men aged 55 or older with a normal digital rectal examination and PSA of 3.0 ng/mL or lower | Finasteride 5 mg a day or placebo, 7 years | Prevalence of prostate cancer over 7 years among men with data for the final analysis: 803 of 4368 (18.4%) on finasteride and 1147 of 4692 (24.4%) on placebo, a 24.8% reduction (95% CI 18.6 to 30.6; P<0.001); Gleason grade 7 to 10 tumours in 6.4% against 5.1% of men |
| PLESS, Proscar label, 20262 | Double-blind, randomised, placebo-controlled, 4-year, multicenter study; label issued by Organon | 3040 men aged 45 to 78 with moderate to severe BPH symptoms and an enlarged prostate | Finasteride 5 mg a day (n=1524) or placebo (n=1516), 4 years | Surgery for BPH 4.6% against 10.1% and acute urinary retention 2.8% against 6.6% (finasteride against placebo, p<0.001); symptom score fell 3.3 points against 1.3 in men who remained on therapy for 4 years (SD 5.8 and 5.6) |
Deeper analysis: the hair loss trials (Kaufman and colleagues, Journal of the American Academy of Dermatology, 1998)
Kaufman and colleagues, writing for the Finasteride Male Pattern Hair Loss Study Group, reported two 1-year trials in 1553 men aged 18 to 41 with male pattern hair loss who received oral finasteride 1 mg a day or placebo, with 1215 continuing in blinded extension studies for a second year.3 Efficacy was evaluated by scalp hair counts, patient and investigator assessments, and review of photographs by an expert panel.3 The authors report that finasteride improved scalp hair by all evaluation techniques at 1 and 2 years (P < .001 against placebo), with hair counts 107 and 138 hairs above placebo in a 1-inch circle of balding vertex scalp, and that placebo gave progressive hair loss.3 Their summary states that "Adverse effects were minimal" in the trials.3 The first author's stated affiliation is the Department of Clinical Research, Merck Research Laboratories, Rahway, New Jersey, and the source text names no sponsor and states no limitations.3 The Propecia label, which reports the same programme to 5 years, adds that all men used a tar-based shampoo during the first 2 years, that hair count was maintained above baseline throughout the 5 years after an initial improvement followed by a slow decline, and that clinical efficacy studies did not include subjects aged 65 and over.1
Deeper analysis: the Prostate Cancer Prevention Trial (Thompson and colleagues, New England Journal of Medicine, 2003)
Thompson and colleagues, of the University of Texas Health Science Center in San Antonio, randomly assigned 18,882 men aged 55 or older to finasteride 5 mg a day or placebo for seven years, five times the Propecia dose.5,1 Prostate cancer was detected in 18.4% of men with final data on finasteride and 24.4% on placebo, a 24.8% reduction in prevalence (95% CI 18.6 to 30.6; P<0.001).5 Tumours of Gleason grade 7, 8, 9 or 10 were more common in the finasteride group, 280 of 757 tumours (37.0%) against 237 of 1068 (22.2%) on placebo.5 The paper states that sexual side effects were more common in finasteride-treated men, whereas urinary symptoms were more common in men receiving placebo.5 Its conclusion states that this possible benefit and a reduced risk of urinary problems "must be weighed against sexual side effects and the increased risk of high-grade prostate cancer".5 The listed funding is grants from the National Cancer Institute (CA35178, CA37429, CA45808), and the source text states no author ties and no limitations.5 The Propecia label reports Gleason score 8 to 10 prostate cancer in 1.8% on finasteride against 1.1% on placebo in this trial, states that 5-alpha reductase inhibitors may increase the risk of development of high-grade prostate cancer, and states that whether the effect of 5-alpha reductase inhibitors to reduce prostate volume, or study-related factors, affected the results has not been established.1
Doses reported in studies and on labels
| Source | Dose | Frequency | Length |
|---|---|---|---|
| Propecia label, hair loss1 | 1 mg | Once daily | 12 months to 5 years in studies |
| Kaufman and colleagues, 19983 | 1 mg | Once daily (1 mg/d) | 1 and 2 years |
| Proscar label, benign prostatic hyperplasia2 | 5 mg | Once a day | 4 years in PLESS |
| Thompson and colleagues, 20035 | 5 mg | Per day | 7 years |
| Olsen and colleagues, 20064 | 5 mg (finasteride arm) | Daily | 24 weeks |
| The app | 1 to 2 mg | Per day | Not stated |
Side effects reported
In three controlled 12-month trials for male pattern hair loss, 1.4% of men taking Propecia (n=945) discontinued because of adverse experiences judged possibly, probably or definitely drug-related, against 1.6% on placebo (n=934).1
| Drug-related adverse experience, year 1 (Propecia label) | Propecia 1 mg (n=945) | Placebo (n=934) |
|---|---|---|
| Decreased libido | 1.8% | 1.3% |
| Erectile dysfunction | 1.3% | 0.7% |
| Ejaculation disorder (decreased volume of ejaculate) | 1.2% (0.8%) | 0.7% (0.4%) |
| Discontinuation due to drug-related sexual adverse experiences | 1.2% | 0.9% |
In the integrated analysis, 36 of 945 men (3.8%) on Propecia reported one or more of these sexual adverse experiences against 20 of 934 (2.1%) on placebo (p=0.04).1 The label states that resolution occurred in men who discontinued therapy and in most of those who continued, and that the incidence of each decreased to 0.3% or less by the fifth year of treatment.1 On a self-administered sexual function questionnaire at month 12, differences favoured placebo in 3 of 4 domains (sexual interest, erections and perception of sexual problems), with no significant difference in overall satisfaction with sex life.1 In the 4-year PLESS trial of 5 mg a day, 3.7% (57 men) on finasteride and 2.1% (32 men) on placebo discontinued because of adverse reactions related to sexual function, and impotence judged possibly, probably or definitely drug related by the investigator was 8.1% against 3.7% in year 1 and 5.1% in both arms in years 2 to 4.2
The Propecia label lists, from post-approval use, sexual dysfunction that continued after discontinuation of treatment, male infertility or poor seminal quality, testicular pain, male breast cancer, depression, and suicidal ideation and behavior, and states that frequency and causal relationship cannot always be reliably established because the reports are voluntary from a population of uncertain size.1 A 2019 systematic review and meta-analysis by Lee and colleagues (Yonsei University, Korea) pooled 15 randomised double-blind placebo-controlled trials with 4,495 subjects given finasteride 1 mg a day or dutasteride 0.5 mg a day for androgenetic alopecia.6 Use of 5-alpha reductase inhibitors carried a 1.57-fold risk of sexual dysfunction (95% CI 1.19 to 2.08), with a relative risk of 1.66 (95% CI 1.20 to 2.30) for finasteride and 1.37 (95% CI 0.81 to 2.32) for dutasteride, the increase not being statistically significant for dutasteride.6 The authors state that as studies into dutasteride were limited, further trials are required.6
Deeper analysis: long-term follow-up for post-finasteride syndrome (Till and colleagues, Urology, 2026)
Till, Tangen, Goodman, Unger and Thompson, of the Fred Hutchinson Cancer Center, linked records of subjects enrolled in the Prostate Cancer Prevention Trial to Medicare claims and queried 22 conditions potentially attributed to post-finasteride syndrome, including sexual and cognitive symptoms.7 Of 18,880 eligible subjects, 15,122 were linked to Medicare and 14,239 of those had one or more years of continuous coverage, with a median follow-up of 20 years and 267,983 person-years.7 Comparing former finasteride use to matched placebo, none of the 22 conditions had a statistically significant association with treatment arm.7 The authors conclude that the anecdotal reports are likely related to the ubiquitous nature of these symptoms in an aging population and reporting bias.7 The Prostate Cancer Prevention Trial dose was 5 mg a day, not the 1 mg of Propecia,5 and the source text of this follow-up states no limitations.7 Funding is listed as grants from the National Cancer Institute, and one author, Unger, reports consulting or advisory relationships with AstraZeneca Pharmaceuticals LP and Eli Lilly and Company.7
The European Medicines Agency's safety committee (PRAC) confirmed suicidal ideation as a side effect of finasteride 1 and 5 mg tablets in May 2025, and states that the frequency is unknown, meaning it is not possible to estimate it from available data.8 EudraVigilance held 325 relevant cases of suicidal ideation, 313 for finasteride and 13 for dutasteride (1 case reported for both), against an estimated exposure of around 270 million patient years for finasteride.8 Wang and colleagues (2025) analysed Mendelian randomization data and the UK Biobank cohort; the Mendelian randomization analysis found finasteride prescription not related to depression or suicide after false discovery rate correction, and the cohort analysis found finasteride use not significantly associated with depression or suicide events.9 Gupta and colleagues (2025) analysed reports to the US FDA Adverse Event Reporting System and detected no significant signals for oral finasteride in 2006 to 2011, but a reporting odds ratio for suicidal ideation of 2.8 in 2013 to 2018 and 5.0 in 2019 to 2023, and wrote that the increase may be linked to heightened awareness of adverse events after the recognition of so-called post-finasteride syndrome in 2012.10
Bloodwork and markers
Sources in this part
In clinical studies of Propecia in men aged 18 to 41, mean serum prostate specific antigen (PSA) decreased from 0.7 ng/mL at baseline to 0.5 ng/mL at month 12.1 In clinical studies of Proscar in older men with BPH, PSA levels decreased by approximately 50%.1 The label states that any confirmed increase from the lowest PSA value while on Propecia may signal the presence of prostate cancer even if PSA levels are still within the normal range for men not taking a 5-alpha reductase inhibitor.1 The label states that mean circulating testosterone and estradiol increased by approximately 15% from baseline and stayed within the physiologic range, and that no clinically meaningful changes in luteinizing hormone, follicle-stimulating hormone or prolactin were detected.1
Regulatory and anti-doping status
Sources in this part
The Propecia label lists pregnancy as a contraindication, stating that finasteride may cause abnormalities of the external genitalia of a male fetus of a pregnant woman who receives it.1 The label cautions women who are or may be pregnant against handling crushed or broken tablets because of possible absorption and potential risk to a male fetus, and states that coated tablets prevent contact with the active ingredient during normal handling.1 In the European Union, EMA's May 2025 review led to a patient card in the packages of 1 mg finasteride tablets and product information about problems with sexual function, which are known side effects and may contribute to mood changes.8
The WADA 2026 Prohibited List, in effect from 1 January 2026, does not contain the word finasteride in its text, and a text search for 5-alpha reductase also returns no match.11 Its S5 class prohibits "All diuretics and masking agents" at all times, in and out of competition, with examples introduced by "Including, but not limited to" and followed by "and other substances with a similar chemical structure or similar biological effect(s)", and the examples named there do not include finasteride.11
Storage and handling
Sources in this part
The Propecia label gives storage at room temperature, 15 to 30 degrees Celsius (59 to 86 degrees Fahrenheit), with the container closed and protected from moisture, and supplies the tablets in bottles with desiccant.1
What is not known
Sources in this part
The Propecia label states that the effect of hepatic impairment on finasteride pharmacokinetics has not been studied, that efficacy of Propecia in the elderly has not been established, and that efficacy in bitemporal recession has not been established.1 It states that the clinical significance of the high-grade prostate cancer findings for use of Propecia by men is unknown, and that the relationship between long-term finasteride use and male breast neoplasia is currently unknown.1 EMA states that the frequency of suicidal ideation with finasteride is unknown.8 The Propecia label states that withdrawal of treatment leads to reversal of effect within 12 months, and in its studies a change from Propecia to placebo (n=48) reversed the hair count increase 12 months later.1
Frequently asked questions
What is the half-life of finasteride?
What is the bioavailability of finasteride?
How long does finasteride take to reach its peak level?
The app lists a time to peak of about 2 hours for finasteride. The Propecia label states that at steady state on 1 mg a day the maximum plasma concentration was reached 1 to 2 hours after the dose, with a mean of 1.3 hours.1
What is finasteride used for?
Finasteride 1 mg (Propecia) is indicated in the United States for male pattern hair loss (androgenetic alopecia) in men only, and finasteride 5 mg (Proscar) for symptomatic benign prostatic hyperplasia in men with an enlarged prostate.1,2 The Proscar label states that it is not approved for the prevention of prostate cancer.2
What dose of finasteride was used in studies?
The hair loss trials in the Propecia label and in Kaufman and colleagues (1998) used 1 mg a day.1,3 The Prostate Cancer Prevention Trial (Thompson and colleagues, 2003) and the Proscar label's PLESS trial used 5 mg a day.5,2 The app lists a typical dose of 1 to 2 mg a day. None of the labels or trials cited here reports a daily dose of 2 mg.
How long does finasteride take to show an effect in studies?
The Propecia label states that in general daily use for three months or more is necessary before benefit is observed.1 In its trials, improvement in patient self-assessment against placebo was seen as early as 3 months (p<0.05) and hair count differences were significant at 6 and 12 months.1 The label states that withdrawal of treatment leads to reversal of effect within 12 months.1
What are the side effects of finasteride?
In three 12-month trials of Propecia 1 mg (n=945), drug-related decreased libido was reported in 1.8% against 1.3% on placebo, erectile dysfunction in 1.3% against 0.7%, and ejaculation disorder in 1.2% against 0.7%.1 In total, 36 of 945 men (3.8%) on Propecia reported one or more of these sexual adverse experiences against 20 of 934 (2.1%) on placebo (p=0.04).1 In the same trials 1.4% on Propecia discontinued because of drug-related adverse experiences against 1.6% on placebo.1 The label also lists post-approval reports of sexual dysfunction that continued after discontinuation, depression, and suicidal ideation and behavior, from a population of uncertain size.1
Does finasteride cause depression or suicidal thoughts?
EMA's safety committee confirmed suicidal ideation as a side effect of finasteride 1 and 5 mg tablets in May 2025, with a frequency that is unknown.8 Wang and colleagues (2025), reported that Mendelian randomization found no relation to depression or suicide after false discovery rate correction and that, in the UK Biobank cohort, finasteride use was not significantly associated with depression or suicide events.9 An analysis of US FDA adverse event reports by Gupta and colleagues (2025) found reporting signals for suicidal ideation in 2013 to 2018 and 2019 to 2023 but not in 2006 to 2011.10
Is finasteride banned by WADA?
Finasteride is not named in the text of the WADA 2026 Prohibited List, which came into effect on 1 January 2026.11 The S5 class of diuretics and masking agents is prohibited at all times and lists its examples as "Including, but not limited to" the substances named, and adds "and other substances with a similar chemical structure or similar biological effect(s)".11
Guides, tools and comparisons
References
- Organon LLC. PROPECIA- finasteride tablet, film coated. DailyMed label, revised 11/2023. DailyMed label
- Organon LLC. PROSCAR- finasteride tablet, film coated. DailyMed label, revised 03/2026. DailyMed label
- Kaufman KD, et al. Finasteride in the treatment of men with androgenetic alopecia. J Am Acad Dermatol 1998. PMID 9777765
- Olsen EA, et al. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol 2006. PMID 17110217
- Thompson IM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003. PMID 12824459
- Lee S, et al. Adverse sexual effects of treatment with finasteride or dutasteride for male androgenetic alopecia: a systematic review and meta-analysis. Acta Derm Venereol 2019. PMID 30206635
- Till C, et al. No evidence of post-finasteride syndrome in 267,983 person-years follow-up in the Prostate Cancer Prevention Trial. Urology 2026. PMID 42628582
- European Medicines Agency. Measures to minimise risk of suicidal thoughts with finasteride and dutasteride medicines. 8 May 2025. EMA news
- Wang J, et al. Finasteride use does not lead to depression or suicide: insights from a large-scale cohort study and Mendelian randomization analysis. J Cosmet Dermatol 2025. PMID 41330881
- Gupta AK, et al. Finasteride use: evaluation of depression and suicide risk. J Cosmet Dermatol 2025. PMID 40082195
- World Anti-Doping Agency. World Anti-Doping Code International Standard Prohibited List 2026. In effect 1 January 2026. WADA 2026 list